Dual-agonist appetite support, without the weekly injection.
Tirzepatide tablets are the oral answer for people who want dual-agonist weight care without a needle, and interest in oral tirzepatide has grown fast. Tirzepatide acts on two gut hormone receptors, GLP-1 and GIP, and clinical trials of the molecule have reported some of the strongest average weight-loss outcomes recorded for an anti-obesity medication. HELiXVi prescribes compounded tirzepatide oral tablets prepared by a US state-licensed compounding pharmacy, after an online consultation with a licensed provider. Compounded oral tirzepatide is not FDA-approved. Mounjaro® and Zepbound® are injectable branded tirzepatide products from Eli Lilly and are different products that we do not supply. Approval is never guaranteed, and individual results vary.
Tirzepatide is a single peptide that acts on two incretin receptors, GLP-1 and GIP, which together influence insulin release, glucose handling, and appetite signaling. Injectable tirzepatide has the deepest evidence base, including large trials reporting category-leading average weight reductions. Oral delivery of peptides is harder, because the stomach degrades them, and oral tirzepatide formulations are designed to protect the molecule through digestion. Published research on the molecule is what should inform your expectations, not marketing claims. GLP-1 and dual-agonist medications carry a boxed warning for thyroid C-cell tumors, and common side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain. Compounded oral tirzepatide is not FDA-approved, and individual results vary.
The people who do best on dual-agonist care are not the ones with the most discipline. They are the ones whose biology finally stopped arguing with the plan. If a weekly injection was the only thing standing between you and that conversation, tirzepatide tablets exist to remove the excuse.
Both forms deliver the same molecule, which acts on the GLP-1 and GIP receptors. Injectable tirzepatide has the most extensive clinical evidence, while oral tirzepatide suits people who prefer a daily tablet. Absorption and dosing differ between routes, so the comparison is a conversation with your prescriber, not a guess. Individual results vary.
Dosing is set by your prescriber and escalated gradually to limit gastrointestinal side effects. We do not publish a self-dosing chart, because the right schedule depends on your health profile and how you respond at each step. Your provider adjusts your dose as treatment progresses.
We do not publish patient testimonials or reviews, and we would be cautious of any seller whose evidence is a reviews page. What we can point you to is published trial evidence about the tirzepatide molecule: large studies have reported substantial average weight reductions in participants when paired with lifestyle change. Trial results describe study populations, not guaranteed individual outcomes.
No. Compounded oral tirzepatide is not FDA-approved. The FDA-approved tirzepatide products are injectable: Mounjaro® and Zepbound® from Eli Lilly. HELiXVi is not affiliated with or endorsed by Eli Lilly and does not supply those branded products.
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain, usually strongest early and easing with gradual titration. Tirzepatide carries a boxed warning for thyroid C-cell tumors and is not appropriate if you or a family member has a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Your provider screens for risks before prescribing.
Candidacy is a clinical decision. Providers generally consider factors like BMI, weight-related health conditions, your medical history, current medications, and previous responses to weight-loss treatment. A licensed provider reviews all of this in your consultation, and approval is never guaranteed.
Compounded oral tirzepatide is prepared by US state-licensed pharmacies and is not FDA-approved. Mounjaro® and Zepbound® are FDA-approved injectable tirzepatide products from Eli Lilly; HELiXVi is not affiliated with or endorsed by Eli Lilly and does not supply those products. Prescription products require an online consultation with a licensed provider; approval is not guaranteed. GLP-1 and dual-agonist medications carry a boxed warning for thyroid C-cell tumors. Common side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain. Individual results vary. This page is educational and is not a substitute for medical advice.
Start your free consultation right now
No clinic visit. Licensed US clinicians. Dispatched within 24 hours of your consultation and payment.